Winona Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

What Is Winona and How Does Its Prescribing Model Work?

Winona operates as an asynchronous-first telehealth service that connects women experiencing perimenopause or menopause with licensed physicians who prescribe hormone replacement therapy. The platform is cash-pay, meaning it does not bill insurance. Patients complete an intake questionnaire, a physician reviews responses, and a prescription is issued if clinically appropriate.

The Async-First Model and Its Tradeoffs

The asynchronous model is convenient but creates a data gap. Clinicians cannot perform physical examinations, cannot auscultate, and rely entirely on self-reported symptom scales. The Menopause Rating Scale (MRS) and the Greene Climacteric Scale are validated patient-reported instruments used in research settings [1], but neither Winona nor any peer-reviewed publication has confirmed that Winona employs these tools systematically during intake.

Validated screening matters because symptom severity determines appropriateness of HRT initiation. The 2022 NAMS Position Statement states: "Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture." [2] The same document cautions that individual cardiovascular and thromboembolic risk must be assessed before prescribing.

Prescribing Oversight

Winona advertises physician oversight rather than relying exclusively on nurse practitioners. State medical board licensure requirements govern this. Physicians prescribing via telehealth must hold an active, unrestricted license in the patient's state of residence under most state telemedicine statutes. The Federation of State Medical Boards maintains a consolidated database of disciplinary actions [3], and no specific Winona-affiliated physician actions appeared in a July 2025 review of that database, though individual physician histories require manual verification.

What Therapies Does Winona Prescribe?

Winona's publicly listed formulary includes transdermal estradiol (patches and gels), oral micronized progesterone (Prometrium or generic equivalent), vaginal estradiol, and compounded bioidentical hormone preparations. Testosterone and DHEA are also offered.

FDA-Approved vs. Compounded Products

FDA-approved transdermal estradiol and oral micronized progesterone carry the strongest evidence base. The NAMS 2022 Position Statement explicitly notes that FDA-approved bioidentical hormones, including 17-beta estradiol and micronized progesterone, have a well-characterized safety and efficacy profile [2]. Compounded preparations, by contrast, lack FDA approval and are not subject to the same manufacturing standards or post-market surveillance.

The FDA has published guidance on compounded hormone therapy, noting that compounded preparations are not proven safe or effective in the way FDA-approved drugs are, and that they carry risks including imprecise dosing [4]. Winona's use of compounded products for patients who cannot tolerate FDA-approved formulations may be clinically defensible in individual cases, but the platform has not published data on what percentage of its prescriptions are compounded versus FDA-approved.

Estrogen Route and Thrombotic Risk

Route of administration carries clinical significance that an intake questionnaire must capture accurately. Transdermal estradiol does not undergo first-pass hepatic metabolism and carries a materially lower risk of venous thromboembolism compared to oral estrogen. A 2010 meta-analysis in the BMJ (N=21 studies) found that transdermal estrogen was not associated with increased VTE risk, while oral estrogen conferred approximately a two-fold increase [5]. Platforms that default to oral formulations without a clear clinical rationale introduce preventable risk.

Winona appears to favor transdermal delivery based on its publicly visible formulary, which aligns with current evidence. However, no prescribing-mix data has been published to confirm the proportion of oral versus transdermal prescriptions written.

Published Outcomes Data: What Exists and What Does Not

This is the most significant gap in evaluating Winona. No peer-reviewed study, retrospective cohort analysis, or independently audited outcomes report has been published on Winona's patient population as of July 2025.

Benchmarks from the Broader HRT Evidence Base

To contextualize what Winona patients might expect, the established trial data is instructive. The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727) found that transdermal estradiol and low-dose oral conjugated equine estrogen both reduced vasomotor symptom frequency compared to placebo over 48 months, with a favorable cardiovascular safety profile in recently menopausal women [6]. The WHI trial (N=16,608) established that certain HRT regimens in older women carried increased risks of breast cancer and cardiovascular events, findings that substantially depend on patient age at initiation and years since menopause [7].

The "timing hypothesis," formalized by Rossouw et al. And echoed by the 2022 NAMS Position Statement, holds that HRT initiated within 10 years of menopause or before age 60 carries a more favorable benefit-risk profile [2][7]. A telehealth platform serving primarily younger perimenopausal women should, in theory, be operating in the favorable window. Whether Winona's intake process accurately identifies timing-of-menopause to apply this logic is not publicly confirmed.

Why Winona's Silence on Outcomes Data Matters

Telehealth menopause platforms that publish transparent outcomes data set a higher standard of accountability. Midi Health, for example, has referenced internal data on symptom improvement in marketing materials, though these too lack peer-reviewed publication. The absence of any published symptom-score improvement rates, treatment discontinuation rates, or adverse-event frequencies from Winona makes independent quality assessment impossible.

A structured framework for evaluating any menopause telehealth platform should include five domains: (1) formulary alignment with NAMS/Endocrine Society guidelines, (2) published or auditable symptom-outcome data, (3) compounded versus FDA-approved prescribing mix, (4) adverse-event reporting mechanisms, and (5) regulatory and complaint-board standing. Winona currently satisfies domain 1 on a surface level but lacks verifiable data on domains 2, 3, 4, and 5.

Regulatory Standing: BBB, LegitScript, and State Boards

Better Business Bureau Profile

Winona holds no BBB accreditation as of July 2025. The BBB profile shows a limited number of filed complaints, most categorized under billing or service delivery rather than clinical safety concerns. The absence of accreditation is not itself a red flag for a telehealth startup but does mean no independent third-party has reviewed its business practices against the BBB's standards.

LegitScript Certification

LegitScript is the primary third-party certification body for online pharmacy and telehealth legitimacy in the United States. LegitScript-certified platforms have demonstrated compliance with applicable laws, a valid pharmacy relationship, and transparent prescribing standards. LegitScript maintains a public database where any platform can be verified [8]. Patients and clinicians should check Winona's current certification status directly at LegitScript's site before initiating care, as certification statuses change.

FDA Warning Letters and Compounding Oversight

The FDA's MedWatch system and its database of warning letters to compounding pharmacies are public [4]. Patients using any compounded HRT preparation, whether from Winona or another platform, should confirm that the compounding pharmacy is licensed under Section 503A or 503B of the Food, Drug, and Cosmetic Act. A 503B outsourcing facility is subject to FDA Current Good Manufacturing Practice (CGMP) standards, which provides a higher level of quality assurance than a standard 503A pharmacy [4].

Patient Complaint Signals

What Complaint Patterns Suggest

Online reviews and complaint aggregators (Trustpilot, Reddit's r/Menopause, Google Reviews) show a pattern common to async telehealth platforms: positive feedback tends to center on convenience and cost, while negative feedback clusters around difficulty reaching physicians for follow-up questions, formulary substitutions without patient notification, and delays in prescription renewal.

These complaint types do not represent clinical safety signals in the traditional pharmacovigilance sense. They do, however, point to potential monitoring gaps. A patient who cannot easily reach a clinician after starting estradiol and noticing unexpected spotting may delay evaluation of endometrial changes longer than is advisable. The Endocrine Society's 2015 Clinical Practice Guideline on Menopause recommends annual follow-up for women on HRT, including endometrial assessment in women with a uterus who experience unscheduled bleeding [9].

The "Is Winona Legit?" Question

Winona appears to be a legitimately operating medical practice that employs licensed physicians and ships from licensed pharmacies. The regulatory concern is not about legality but about clinical rigor. Legitimate in the legal sense is a lower bar than evidence-aligned in the clinical sense.

The practical answer to "Is Winona legit?" requires separating two questions: (a) Is it operating within the law? Apparently yes, based on available public information. (b) Does it meet the clinical standard of care for menopause HRT management? That question cannot be answered without published outcomes data, transparent prescribing protocols, and independent audit.

How Winona Compares to NAMS and Endocrine Society Guidelines

NAMS 2022 Position Statement Alignment

The 2022 NAMS Position Statement recommends individualized therapy based on symptom type, severity, age at menopause, time since menopause, and personal/family history [2]. It explicitly states that "for women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms." [2]

An async intake questionnaire can capture age, years since menopause, symptom type, and some family history, but cannot replicate a thorough clinical history and physical examination. Contraindications including unexplained vaginal bleeding, active liver disease, personal history of estrogen-sensitive malignancy, or active thromboembolic disease require nuanced assessment. Whether Winona's intake form screens adequately for each of these is not publicly documented.

Endocrine Society Guideline Specifics

The Endocrine Society's 2015 guideline on menopause management recommends against routine use of compounded bioidentical hormones when FDA-approved alternatives exist, citing lack of safety and efficacy data [9]. The guideline states: "We recommend against the routine use of compounded bioidentical hormones because of concerns about safety, efficacy, and quality." [9] Winona's inclusion of compounded products in its formulary places part of its prescribing practice outside the recommendation of this major guideline.

Progesterone Co-Prescribing

In women with an intact uterus, estrogen must be co-prescribed with a progestogen to prevent endometrial hyperplasia and carcinoma. The WHI trial data confirms this requirement [7]. Oral micronized progesterone (e.g., Prometrium 200 mg daily for 12 days per cycle or 100 mg nightly continuously) is the preferred formulation under NAMS guidance because it does not carry the adverse cardiovascular signal associated with medroxyprogesterone acetate [2]. Winona's formulary includes oral micronized progesterone, which aligns with this guidance.

Cost Structure and Access Considerations

Winona charges a monthly subscription fee that covers physician consultations and, in some tiers, medication costs. As of mid-2025, published pricing ranges from approximately $99 to $199 per month depending on the treatment plan. No insurance billing means patients bear the full cost directly, which may limit access for lower-income patients with menopause symptoms who qualify for HRT under evidence-based criteria.

The cost-access tradeoff matters clinically. A 2023 JAMA Internal Medicine analysis found that cost was a primary barrier to menopause care for approximately 34% of surveyed U.S. Women [10]. Cash-pay platforms like Winona lower the barrier of specialist access but may shift cost burden to patients who would otherwise benefit from insurance coverage.

What Prescribers and Patients Should Know Before Using Winona

For Patients

Before initiating HRT through any telehealth platform, patients should confirm that the prescribing physician holds an active license in their state, that the pharmacy dispensing medications is licensed and verified via the NABP's (.pharmacy domain) database, and that the platform has a clear protocol for managing adverse events and unscheduled bleeding. The NAMS "Menopause Practitioner Locator" provides access to in-person practitioners who may be better positioned for complex cases [2].

For Clinicians Reviewing Telehealth-Initiated HRT

Patients who have been started on HRT by a telehealth platform and then present to an in-person clinician for follow-up should have their risk factors re-assessed against the NAMS 2022 and Endocrine Society 2015 criteria. Particular attention should go to: baseline blood pressure, personal or family history of VTE, breast cancer risk (using the Tyrer-Cuzick model or Gail model), and symptom-score documentation at baseline. Ideally, a MRS or Greene Climacteric Scale score should be obtained to establish a treatment-response benchmark [1].